Sort   by:  
 Page size 
GenomicsInstitut Curie Neuroblastoma data access Committee
Data Access Committee EGAC00001000319
EGAC00001000319 | EGA
GenomicsAMC Dept. Oncogenomics
Data Access Committee EGAC00001000321
EGAC00001000321 | EGA
Genomicsena-DATASET-AMC-11-05-2015-14:58:16:693-185 - samples
The majority of neuroblastoma patients have tumors that initially respond to chemotherapy, but a large proportion of patients will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole genome sequencing of 23 paired diagnostic and relapsed neurobla...
EGAD00001001360 | EGA
GenomicsNeuroblastoma relapse trio series from the AMC
The majority of neuroblastoma patients have tumors that initially respond to chemotherapy, but a large proportion of patients will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole genome sequencing of 23 paired diagnostic and relapsed neurobla...
EGAS00001001183 | EGA
Genomicsena-DATASET-CURIE-LC-04-05-2015-16:47:47:270-89 - samples
Neuroblastoma, a clinically heterogeneous pediatric cancer, is characterized by distinct genomic profiles but few recurrent mutations. As neuroblastoma is expected to have high degree of genetic heterogeneity, study of neuroblastoma's clonal evolution with deep coverage whole-genome sequencing of di...
EGAD00001001356 | EGA
GenomicsInstitut Curie Neuroblastoma Whole Genome Sequencing Diagnosis Relapse
Neuroblastoma, a clinically heterogeneous pediatric cancer, is characterized by distinct genomic profiles but few recurrent mutations. As neuroblastoma is expected to have high degree of genetic heterogeneity, study of neuroblastoma's clonal evolution with deep coverage whole-genome sequencing of di...
EGAS00001001184 | EGA
Sort   by:  
 Page size